Description
Indication & Scope
Insulin icodec Injection improves glycemic control in adult patients with type 2 diabetes mellitus.
- Mechanism: Ultra-long acting basal insulin analog with fatty acid side chain modification, binds to albumin in peripheral circulation to achieve steady 7-day sustained insulin release. Regulates hepatic glucose output and peripheral glucose uptake to lower fasting blood glucose.
- Drug class: Long-acting human insulin analog, anti-diabetic endocrine agent.
- Clinical use: Once-weekly basal insulin therapy for glycemic management in adults with type 2 diabetes mellitus.
| Generic Name | Insulin icodec Injection |
| Brand Name | Awiqli |
| Ingredient | Insulin icodec Injection |
| Dosage Form | Injection |
| Package | 1ml: 700 units pen/box; 1.5ml: 1050 units pen/box; 3ml: 2000 units pen/box |
| Conditions Treated | Type 2 diabetes mellitus in adult patients |
| Taboos | 1. Severe hypersensitivity to insulin icodec or injection excipients
2. Recurrent severe hypoglycemia with unidentifiable causes 3. Diabetic ketoacidosis |
| Place of origin | Brennum Park 1, DK-3400 Hillerød, Denmark |
| Prescription type | Prescription-only |
| Storage Conditions | Unopened pens: 2°C to 8°C refrigeration. In-use pens: store below 30°C away from sunlight for up to 8 weeks. Do not freeze. |
| Manufacturer | Novo Nordisk A/S, Ltd. |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | SJ20240017; SJ20240018; SJ20240019 |
| Approval Date | Jun 18, 2024 |
| Shelf Life | 36 months |
How to use ?
Recommended Dose: Subcutaneously once weekly, titrate weekly based on fasting blood glucose levels to target glycemic goals.
Time: Fixed same day and same time once every 7 days, subcutaneous injection into abdomen, thigh or upper arm.
Instructions for use:
1. Rotate injection sites to prevent lipohypertrophy.
2. Monitor fasting blood glucose to adjust weekly dosage.
3. Educate patients on hypoglycemia recognition and emergency treatment.
4. Do not mix with other insulin formulations in the same injection pen.
Interaction:
1. Sulfonylureas, SGLT-2 inhibitors increase hypoglycemia risk.
2. Corticosteroids, beta-agonists elevate blood glucose and reduce insulin efficacy.
3. Beta-blockers mask hypoglycemia warning symptoms.
Side effects:
1. Common: Hypoglycemia, injection site reactions, weight gain, lipohypertrophy
2. Severe: Severe anaphylactic hypersensitivity, severe prolonged hypoglycemia, peripheral edema
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What is the clinical use of Insulin icodec Injection?
It improves glycemic control in adult patients with type 2 diabetes mellitus.
How often is the Insulin icodec Injection given?
Subcutaneous injection once every 7 days.
How to store in-use Insulin icodec Injection?
Store below 30°C away from sunlight and use within 8 weeks.
What is the most common adverse reaction of Insulin icodec Injection?
Hypoglycemia is the most frequent side effect.
Awiqli® | Insulin icodec Injection | Type 2 Diabetes | DengYueRX
INN: Insulin icodec Injection
Indications: Improve glycemic with type 2 diabetes
Dosage Form: Injection
Strength: 1ml: 700 units; 1.5ml: 1050 units; 3ml: 2000 units
